Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
about
Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems.Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitroImmunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicityImmune response to Lactobacillus plantarum expressing Borrelia burgdorferi OspA is modulated by the lipid modification of the antigenCellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trialFrequent associations between CTL and T-Helper epitopes in HIV-1 genomes and implications for multi-epitope vaccine designsLymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challengeAdenovirus hexon protein is a potent adjuvant for activation of a cellular immune response.Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.TLR-based immune adjuvants.Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individualsEffect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.Novel peptide-based HIV-1 immunotherapy.Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination constructIdentification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIVInduction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine.Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products.Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cellsImmunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact.Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells.Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer.Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation.Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research.Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice.
P2860
Q26748776-15983DD7-5DE6-4FDB-9A0C-85BF73D5BF48Q27478007-08318C85-7262-4AFA-AB94-55D1CF2F8C54Q28749845-174C6188-0D53-4619-8AD5-7AF532A7D184Q28751429-F751D4F1-E9FE-48B7-BDB9-4A46EBB788C7Q33294821-993CB835-530B-4196-AE63-D7B7A5E525C1Q33652911-9239FD86-097E-46AC-8DB6-F481CD6635CBQ33910741-AEDEF463-462B-43FE-B9AA-EF98DED96DF1Q34327129-D0C9D4D6-6702-44D5-8664-058869D641BAQ34348731-04B14705-5A1E-4CC7-8679-FEACB22224B8Q34400322-681F123B-0816-41CE-AF15-4873DD163EC4Q34592982-A9B6669A-5EFD-4FBF-A43F-CBE8FF576A37Q34742548-C724FFEE-95F5-40B4-AD73-38EFE7081C84Q34999946-A725EBC4-66BA-4E01-8DD6-CF197C803E8CQ35684864-9FB03320-EB1F-44DB-83C4-A79F9B31066BQ35886752-0344FC7F-6249-482C-9193-E6EE17AEAC90Q36473740-E99DF442-B04E-4867-9A3A-21A355E71987Q36520832-CF6E72A6-E437-45D6-8D8F-020BFE0B09F1Q36616720-75217F60-B141-48C4-86E0-DF7C5BFD9F4AQ36910003-30960BBE-A7D9-43C3-B7BD-5303F2DECA92Q37213029-252C02B4-4EE3-4A6D-97DA-DC5DE13B23BAQ37216571-49EA9BFF-1259-4768-9F61-D2C7C461C432Q37385041-AC1E8EB5-B5B9-4DB6-989F-DE78AC43C34EQ37661001-599ECA0A-FE0D-44C9-B2FC-27C694533055Q37712684-3FED388A-B796-4481-8CDE-4BC0F7F1CEFBQ38153040-59FF096E-D7F9-4FCA-AC21-272A59722D79Q38279548-0240125C-195A-4471-8BFB-51AA02B2F813Q39699425-AE405E88-ED2C-4889-B512-19B2632B2605Q40054175-08ED2A7C-EBB0-42BA-96A1-34381F38A1F9Q40144775-5D140103-45C2-4D11-8281-46DCD2921B8FQ40749248-314819B5-868A-4D7E-9D0A-E0C34239C644Q40840314-C13CA43E-27FC-4F29-8D55-35F794025B89Q41195668-055FC02D-8593-41F3-8E68-FAAA71276AE6Q42205079-5607C89D-EBDC-40B6-B0B3-DE7BBDD90DB9Q44144363-903E1D08-5260-492F-9EAE-E6EDEA38EBB3Q44260427-533025D5-F7B7-47F7-967C-C830284268A8Q47886696-AF1BD337-1206-4FD3-90CD-BC467CF413B9
P2860
Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Multiepitopic B- and T-cell re ...... rus type 1 lipopeptide vaccine
@ast
Multiepitopic B- and T-cell re ...... rus type 1 lipopeptide vaccine
@en
type
label
Multiepitopic B- and T-cell re ...... rus type 1 lipopeptide vaccine
@ast
Multiepitopic B- and T-cell re ...... rus type 1 lipopeptide vaccine
@en
prefLabel
Multiepitopic B- and T-cell re ...... rus type 1 lipopeptide vaccine
@ast
Multiepitopic B- and T-cell re ...... rus type 1 lipopeptide vaccine
@en
P2093
P2860
P1433
P1476
Multiepitopic B- and T-cell re ...... rus type 1 lipopeptide vaccine
@en
P2093
B Charmeteau
H Gahéry-Ségard
H Gras-Masse
H Poncelet
J G Guillet
P2860
P304
P356
10.1128/JVI.74.4.1694-1703.2000
P577
2000-02-01T00:00:00Z